Paratek Pharmaceuticals (PRTK) Presents New NUZYRA Data

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. BROS
3. ARM
4. FIS
5. QCOM
6. EXPE
7. CPAY
8. PAYC
9. SNAP
10. FSLY

Go back to Paratek Pharmaceuticals (PRTK) Presents New NUZYRA Data

Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2022

October 13, 2022 4:05 PM EDT

Highlights include data from non-clinical and microbiology programs and real-world patient use

BOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announces that new data from the NUZYRA® (omadacycline) non-clinical and investigator-initiated research programs will be presented at IDWeek 2022.

The hybrid conference will be held from Oct. 19-23 at the Walter... More